Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Attacking Drug-Resistant Bacteria by Targeting the BAM Complex

Scientists report that improved understanding of the way in which hundreds of different types of disease-causing bacteria operate could help pave the way to tackling their effects. University of Leeds researchers led by Sheena Radford, Ph.D., and Neil Ranson,

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Scientists report that improved understanding of the way in which hundreds of different types of disease-causing bacteria operate could help pave the way to tackling their effects.

University of Leeds researchers led by Sheena Radford, Ph.D., and Neil Ranson, Ph.D., have uncovered new information about the operation of a protein complex called BAM, the beta-barrel assembly machinery, which helps insert other bacterial proteins into the bacteria's outermost protective layer. For bacteria to spread diseases, they need to form an outer membrane, or they cannot survive in the harsh environments in which they live.

The BAM complex plays a crucial role in this process, facilitating the insertion of a myriad of proteins into this layer that are required for it to work properly as a barrier, protecting the bug from attack by antibiotics. With their new results, researchers in the Astbury Centre for Structural Molecular Biology say it may be possible to design drugs that could target the BAM complex to stop it operating.

“This is a complex molecular machine involved in keeping bacteria alive, and we know that mutations in it are lethal to the bacteria,” said Dr. Ranson. “Some beautiful work by other labs has shown that BAM exists in two different shapes, an open and closed form, but the open form seemed to require part of the complex to fall apart. Our work shows for the first time the intact BAM complex in this open state. Now that we have been able to see the intact structure in this way, it gives us new clues about how BAM works and about how to develop ways to stop it functioning.”

Dr. Radford, director of the University's Astbury Centre, noted that “If BAM cannot do its job, bacteria won't survive and they would be prevented from spreading diseases. The challenge, now we understand more about how BAM works, is for the scientific community to develop drugs which can target it and replenish our shrinking arsenal of antibiotics to treat bacterial infections.”

The new understanding is expected to contribute to ongoing work to find new ways to kill bacteria that have become increasingly resistant to drugs developed in 20th century. Antibacterial resistance has become a major issue in recent years, with many drugs developed to combat infections from whooping cough to salmonella, and a wide range of hospital-acquired infections, losing their effectiveness.

Previously scientists have used X-ray crystallography, which has been the mainstay of structural discovery for several decades, to show that the barrel-shaped BAM complex could exist in both open and closed forms. The BAM complex sits within the outer membrane of Gram-negative bacteria and inserts other proteins into the membrane, where they are needed to form a functional protective layer. How this happens is not properly understood, but the change in shape is thought to be essential to allow its client proteins to enter the membrane.

Using highly advanced electron microscopes, Drs. Radford and Ranson now have seen the structure of BAM in an open state by rapidly freezing the complex from solution. The team published its study (“Lateral Opening in the Intact β-Barrel Assembly Machinery Captured by Cryo-EM”) in Nature Communications.

Previous structures of the open state all lacked one of the five proteins that make the full BAM complex, called BamB. The new results show that opening of the BAM barrel can happen with BamB there, and this changes the way scientists think about how BAM might work.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →